Investors expect Qianjiang Yongan Pharmaceutical to underper...
Investors expect Qianjiang Yongan Pharmaceutical to underperform the broader industry, leading to a low P/S ratio. The company's declining revenue and weak share price performance could potentially push the P/S ratio even lower.
Benign Growth For Qianjiang Yongan Pharmaceutical Co., Ltd. (SZSE:002365) Underpins Stock's 27% Plummet
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment